{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-218522","form_type":"8-K","ticker":"RMD","cik":"0000943819","company_name":"RESMED INC","filed_at":"2022-08-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:58.724333+00:00","generated_at":"2026-06-24T01:16:37.728754+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"ResMed Q4 revenue $914.7M (+4% YoY); dividend up 5% to $0.44; acquires MEDIFOX DAN for $1B","bullets":["Q4 revenue $914.7M (+4% YoY, +8% constant currency); GAAP diluted EPS $1.33.","Full-year revenue $3.58B (+12% YoY, +13% constant currency); GAAP EPS $5.30.","Quarterly dividend raised 5% to $0.44/share, payable Sept 22, record Aug 18.","Announced $1B acquisition of MEDIFOX DAN, a German out-of-hospital software company; expected close by Dec 31, 2022.","Lucile Blaise promoted to President of Sleep & Respiratory Care effective July 1, 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-218522","json":"https://secwatch.observer/filing/0001193125-22-218522.json","markdown":"https://secwatch.observer/filing/0001193125-22-218522.md","text":"https://secwatch.observer/filing/0001193125-22-218522.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/943819/000119312522218522/0001193125-22-218522-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/943819/000119312522218522/d392713d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T01:16:37.728754+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}